Signaling Molecule IL-38 Can Reduce Inflammation, May Be Therapy Target, Study Finds
Interleukin-38, an immune signaling molecule known as IL-38, can reduce the inflammatory activity of a type of immune cells involved in primary Sjögren’s syndrome (pSS), and may be a therapeutic target for this condition, a new study suggests. The study, “Blockade of Th17 response by…